Quantcast

Latest drug discovery Stories

2014-08-07 16:28:19

Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced second quarter 2014 financial results. Clinical Developments and Anticipated Milestones -- Apatorsen -- The OncoGenex apatorsen development program includes seven Phase 2 trials in four tumor types,...

2014-08-05 08:34:27

Supports progression of this first-in-class anti-TLR4 monoclonal antibody into clinical proof of concept study as a potential personalized medicine for rheumatoid arthritis GENEVA, August 5, 2014 /PRNewswire/ -- Novimmune SA, a company focused on the discovery and development of antibody-based drugs to benefit patients with inflammatory, auto-immune disorders, and cancer announces today the completion of a comprehensive Phase I clinical trial investigating the pharmacokinetics,...

2014-08-05 08:33:19

SAN FRANCISCO, Aug. 5, 2014 /PRNewswire/ -- Perlstein Lab PBC, a San Francisco-based public benefit corporation whose mission is precision orphan drug discovery, just closed a $2 million seed round. The round was co-led by the clinical-stage orphan drug developer Retrophin, Inc. and the Wilsey family, which is personally affected by an orphan disease. http://photos.prnewswire.com/prnvar/20140805/133384 One in 12 people suffer from an orphan disease, yet 95% of orphan diseases have...

2014-08-05 04:21:27

NESS ZIONA, Israel, August 5, 2014 /PRNewswire/ -- Atox Bio today announced that the European Commission has granted AB103 (Sodium acetate salt of the synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH) orphan medicinal product designation (EU/3/14/1294) for the treatment of necrotizing soft tissue infections. Atox Bio is represented in the EU by Dr. Ulrich Granzer as agent. In addition to a 10-year period of marketing exclusivity in the EU after...

2014-08-04 16:26:08

SARASOTA, Fla., Aug. 4, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has been selected to present at the Next Generation Track at BioPharm America 2014 in Boston (Sept. 22-24, 2014) at The Boston Marriott Copley Place. http://photos.prnewswire.com/prnvar/20140804/133073 Michael Mullan, MBBS, PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will present preclinical and clinical data for anatabine citrate, a small molecule...

2014-08-04 12:30:57

LONDON, Aug. 4, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Restless Legs Syndrome Global Clinical Trials Review, H1, 2014 http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/restless_legs_syndrome_global_clinical_trials_review.html Restless Legs Syndrome Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, "Restless Legs Syndrome Global Clinical Trials Review, H1, 2014" provides data on the...

2014-07-31 16:28:08

SARASOTA, Fla., July 31, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced today that it has initiated the development of its lead molecule, Anatabine Citrate, in Europe; and that it has selected Quotient Clinical, The Translational Pharmaceutics Company, based in the United Kingdom (UK) to run its early development programs. http://photos.prnewswire.com/prnvar/20140731/132375 The Company expects to file a Clinical Trial Application (CTA) by the end of...

2014-07-31 08:35:06

BOSTON and NOTTINGHAM, England, July 31, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., and XenoGesis Ltd., have announced a collaboration that will support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage. Molecular Profiles' pharmaceutical development services will be supported by XenoGesis' expertise in preclinical drug metabolism and pharmacokinetics...

2014-07-30 23:05:41

Data addresses key issues associated with effective translation, translocation and secretion of therapeutic proteins in mammalian cell lines Geneva, Switzerland (PRWEB) July 30, 2014 Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development, announced today new data from the Company’s SURE CHO-Mplus Libraries™ will be presented at the 10th Annual Cell Line Development and Engineering conference being held,...

2014-07-30 12:27:58

However, Exit of Major Companies Will Lead to Competitive Volatility, According to Findings from Decision Resources Group BURLINGTON, Mass., July 30, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States preclinical animal research imaging system market will be significantly driven by the trend toward multimodality imaging, such as combining computed tomography and magnetic resonance imaging with nuclear imaging and optical imaging. This demand stems from the need for...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related